Zecef Suspension (Cefuroxime axetil)

Description

Zecef Suspension contains Cefuroxime Axetil, an oral prodrug of Cefuroxime belonging to the second-generation cephalosporin class of beta-lactam antibiotics, formulated as a dry powder for oral suspension specifically designed for pediatric patients who cannot swallow tablets, providing a palatable fruit-flavored liquid formulation that delivers the same broad-spectrum antibacterial coverage as the tablet form after hydrolysis of the axetil ester moiety in the intestinal mucosa to release the active Cefuroxime. It works by binding to penicillin-binding proteins (PBPs) on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis, thereby disrupting cell wall integrity and leading to bacterial lysis and death, and demonstrates enhanced stability against many beta-lactamases compared to first-generation cephalosporins, providing effective coverage against both gram-positive organisms (Streptococcus pneumoniae, Staphylococcus aureus) and gram-negative organisms (Haemophilus influenzae, Moraxella catarrhalis, E. coli, Klebsiella). It is indicated for the treatment of upper and lower respiratory tract infections (pharyngitis, tonsillitis, sinusitis, otitis media, bronchitis, pneumonia), urinary tract infections, skin and soft tissue infections, and Lyme disease in pediatric patients, with the suspension typically administered as 125mg/5mL or 250mg/5mL in weight-based doses of 10–15mg/kg twice daily for most infections. The suspension should be shaken well before use, taken with food to enhance bioavailability and reduce gastrointestinal side effects, stored in the refrigerator after reconstitution and used within 10 days; it is generally well tolerated with diarrhea, nausea, and vomiting being the most common side effects, and is contraindicated in patients with hypersensitivity to cephalosporins or penicillins due to potential cross-reactivity.